Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Late stage milestones

Late stage milestones

Company Product Indication Event Milestone
Accentia (NASDAQ:ABPI) Biovaxid Non-Hodgkin's lymphoma (NHL) Interim Ph III data Mar 08
Accentia (NASDAQ:ABPI)/PPD (NASDAQ:PPDI) SinuNase Chronic sinusitis Ph III data; submit NDA 2008
Acorda (NASDAQ:ACOR) Fampridine-SR Multiple sclerosis (MS) Ph III data 2Q08
Actelion (SWX:ATLN) Tracleer bosentan Pulmonary arterial hypertension (PAH) in sickle cell disease Ph III data 2008
Actelion (SWX:ATLN) Veletri tezosentan Acute cardiovascular care Ph III data 2H08
Acusphere (NASDAQ:ACUS)/ Nycomed Imagify (AI-700) Detect coronary heart disease (CHD) Submit NDA Early 08
Addrenex/Sciele (NADAQ:SCRX) Clonicel clonidine Attention-deficit hyperactivity disorder (ADHD Ph III data 2H08
Adventrx (AMEX:ANX) Vinorelbine emulsion(ANX-530) Cancer Pivotal (bioequivalence) trial data 1Q08
AGI Therap (ISE:A9I; LSE:AGI) Rezularar arverapamil (AGI-003) Irritable bowel syndrome (IBS) Ph III data 2H08
Alizyme (LSE:AZM) Renzapride (ATL-1251) IBS Ph III data April 2008
Alizyme (LSE:AZM)/ Colal-Pred prednisolone Ulcerative colitis (UC) Ph III data (2Q08); submit 2Q08; 2H08
Schering-Plough (NYSE:SGP) metasulphobenzoate MAA
ALK Abello (CSE:ALK-B)/ Grazax grass pollen allergen Grass pollen allergy Submit regulatory application 2008
Schering-Plough (NYSE:SGP) tablet in Europe
Alliance (LSE:APH) Isoprelor misoprostol (APL202) Induce labor Submit MAA 2H08
Alpharma (NYSE:ALO) ALO-01 extended-release opioid Pain Submit NDA 1H08
Amgen (NASDAQ:AMGN)/ Aranesp darbepoetin alfa/ Anemia FDA panel mtg (ongoing 1Q08
Johnson & Johnson (NYSE:JNJ) Procrit epoetin alfa pharmacovigilance review of ESAs)

Read the full 2969 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers